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ABSTRACT
Background. Cholesterol lowering drugs HMG-CoA reductase inhibitors (statins)
and PPARα activators (fibrates) have been shown to reduce host inflammation via
non-disease specific immunomodulatory mechanisms. Recent studies suggest that
commonly prescribed drugs in general practice, statins and fibrates, may be beneficial
in influenza-like illness related mortality. This retrospective cohort study examines the
association between two lipid lowering drugs, statins and fibrates, and all-cause 30-day
mortality following a medically attended acute respiratory illness (MAARI).
Methods. Primary care patient data were retrospectively extracted from the UKClinical
Practice Research Datalink (CPRD) database. The sample comprised 201,179 adults
aged 30 years or older experiencing a MAARI episode. Patient exposure to statins
or fibrates was coded as separate dichotomous variables and deemed current if the
most recent GP prescription was issued in the 30 days prior to MAARI diagnosis.
Multivariable logistic regression and Cox regression were used for analyses. Adjustment
was carried out for chronic lung disease, heart failure, metformin and glitazones,
comorbidity burden, socio-demographic and lifestyle variables such as smoking status
and body mass index (BMI). Statistical interaction tests were carried out to check for
effect modification by gender, body mass index, smoking status and comorbidity.
Results. A total of 1,096 (5%) patients died within the 30-day follow up period.
Of this group, 213 (19.4%) were statin users and 4 (0.4%) were fibrate users. After
adjustment, a significant 35% reduction in odds [adj OR; 0.65 (95% CI [0.52–0.80])]
and a 33% reduction in the hazard [adj HR: 0.67 (95% CI [0.55–0.83])] of all-cause
30-day mortality following MAARI was observed in statin users. A significant effect
modification by comorbidity burden was observed for the association between statin
use and MAARI-related mortality. Fibrate use was associated with a non-significant
reduction in 30-day MAARI-related mortality.
Conclusion. This study suggests that statin use may be associated with a reduction
in 30-day mortality following acute respiratory illness that is severe enough to
merit medical consultation. Findings from this study support and strengthen similar
observational research while providing a strong rationale for a randomised controlled
trial investigating the potential role of statins in acute respiratory infections.
How to cite this article Joshi et al. (2016), A UK general practice population cohort study investigating the association between lipid low-
ering drugs and 30-day mortality following medically attended acute respiratory illness. PeerJ 4:e1902; DOI 10.7717/peerj.1902
Subjects Epidemiology, Evidence Based Medicine, Infectious Diseases, Pharmacology, Statistics
Keywords Fibrates, Lipid lowering drugs, statins, mortality, MAARI, Acute respiratory illness,
Cohort study, CPRD
INTRODUCTION
Globally, an estimated 3.9 million people are killed annually due to acute respiratory
infections (ARI). Moreover, specific respiratory infections such as influenza and respiratory
syncytial virus (RSV) aremajor contributors to themortality and burden fromARI (Legand,
Briand & Shindo, 2014). Statins are competitive inhibitors of 3-hydroxy-3-methylglutaryl
coenzyme A (HMG-CoA) reductase and are used as lipid lowering drugs to reduce plasma
cholesterol (Kwak et al., 2000) and a reduction in chronic inflammation has been reported
following their administration in hypercholesterolaemic and normocholesterolaemic
individuals (Vaughan, Murphy & Buckley, 1996). In vivo studies demonstrating the ability
of statins to repress MHC-II expression, inhibit T cell activation, and limit the release
of pro-inflammatory cytokines further suggest that statins have immunosuppressive
and immunomodulatory applications (Mach, 2002; Raggatt & Partridge, 2002). Fibrates
(bezafibrate, ciprofibrate, fenofibrate and gemfibrozil) are prescribed as first-line therapy
in patients with severe hypertriglyceridaemia (Miller & Spence, 1998). ARIs trigger a host
inflammatory immune response and can cause excessive secretion of pro-inflammatory
cytokines resulting in a cytokine storm, which can increase the risk of complications
and mortality. Statins and fibrates could potentially interfere with molecular pathways
in influenza infection, reducing secretion of pro-inflammatory cytokines, reducing
inflammation, limiting the onset of a cytokine storm and thus potentially reducing
morbidity and mortality (Fedson, 2006; Jain & Ridker, 2005). These properties of statins
and fibrates could be advantageous in the clinical treatment and management of ARIs
especially as they have been used in clinical practice for years and have well established
safety profiles. Therefore the aim of this study was to investigate the association between
two lipid lowering drugs, statins and fibrates, and all-cause 30-day mortality following a
medically attended acute respiratory illness (MAARI).
METHODS
Data source
This study uses data obtained from the Clinical Practice Research Datalink (CPRD), a large
population based observational and interventional research service providing anonymised
UK primary care patient data. General practices that choose to participate in CPRD are
required to record all instances of clinical diagnoses, morbidity events, abnormal test results
and therapeutic information including prescription information, dosages and methods
of administration. Furthermore, additional information is also recorded, such as weight,
height, blood pressure measurements and lifestyle factors (Herrett et al., 2010), making it
the ideal data source for this study. Ethical approval for research involving CPRD data
for this study was obtained from the CPRD Independent Scientific Advisory Committee
(ISAC) (ISAC Protocol Number: Protocol 11_14R).
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Figure 1 Diagrammatic representation of retrospective cohort study design.
Study design and population
The CPRD data represent a primary care patient cohort and this study was conceptualised
as a retrospective cohort study, in which nested case-control and survival analyses were
conducted to investigate the research question (Fig. 1). The source population for the
present study consisted of all patients registered with general practices contributing to
CPRD.
Following a preliminary exploration of prescribing patterns for statins and fibrates,
the study period was defined as 1st January 2008 to 31st December 2013. All participants
aged 30 years and older with a record of MAARI (Appendix S1) within the study period
were included in the present study sample and within this group, patients classified as
current statin users based on prescription records were identified. It is assumed that all
patients in the study sample that were treated with statins, were clinically indicated for
satin prescription (most likely for primary or secondary cardiovascular disease prevention)
and that statin prescription implies the use of statins. Those without statin prescription
were assumed to be non-users.
The most recent MAARI diagnosis date was used for each patient and even though
MAARI could recur during the study period, each patient was only counted once in the
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study. The start of the 30-day follow up began from theMAARI index date (date of MAARI
event as recorded by the physician).
Data variables
The individual’s exposure to either statins or fibrates in the 30 days prior to the MAARI
episode index date was coded as separate binary variables (yes/no). The outcome of
interest was all-cause mortality occurring in the 30 days following the MAARI index
date. From a list of covariates related to both the exposure and outcome of interest, we
evaluated the following comorbidities as potential confounders: myocardial infarction,
heart failure, peripheral vascular disease, chronic lung disease and hypertension (all coded
as dichotomous variables). In addition we adjusted for total comorbidity burden using
a weighted Charlson’s comorbidity index (CCI) (Schneeweiss & Maclure, 2000). The CCI
scores thus derived were further categorised into 4 levels (0, 1–2, 3–5, >5) for inclusion
in the multivariable analysis as a categorical variable. We adjusted for the following drug
covariates: glitazones, metformin, beta blockers, ACE inhibitors and angiotensin receptor
blockers (ARBs). Finally, we included age, sex, body mass index (BMI) and smoking status
as socio-demographic and lifestyle variables, while the presence of an HbA1c measurement
was used as a proxymeasure of healthcare seeking behaviour (Appendix S1 includes detailed
variable definitions). For chronic conditions, we considered a diagnosis of that particular
condition at any point prior to the MAARI episode index date. For drug covariates, only
current exposures were considered. ‘Current’ was defined as the most recent prescription
in the 30 days prior to the MAARI index date.
These covariates were selected for adjustment based on a combination of what other
researchers had suggested/used, consultation with clinicians and clinical indications as per
the British National Formulary and NICE guidelines (British National Formulary, 2014;
NICE clinical guideline 181, 2014).
Given that statin prescription is a choice, apart from the medical indications for statin
therapy, certain behavioural factors may be related to statin use. Factors related to statin
use such as underlying cardiovascular comorbidity are easier to record, measure and adjust
for. However, behavioural factors and lifestyle preferences related to statin use are more
difficult to measure accurately. We adjust for the covariates that we have been able to
measure (described above). We discuss our findings in the context of those variables that
we may not have been able to measure and adjust for.
For variables with <5% missing data, a complete case analysis approach was adopted;
for variables with >5% of missing data, a dummy variable was created to represent missing
data.
Analysis
Descriptive analysis to summarise data characteristics, identify potential anomalies and
quantify missing data was conducted. To assess the average treatment effect across patients
treatedwith statins and fibrates,multivariable logistic regression andCox regressionmodels
were constructed to investigate the association between statins and fibrates and 30-day
mortality following MAARI. Proportional hazard assumptions were checked using log–log
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plots and the Schoenfeld global test. Collinearity was assessed using the variance inflation
factor. An a priori decision was taken to include age, sex and current metformin and
glitazone use (based on previously reported immunomodulatory activity and likelihood of
co-prescription for diabetes mellitus (Fedson, 2009)) in all multivariable models regardless
of statistical significance. Themodels were constructed as follows:Model A included a priori
variables, all drug covariates, all comorbidity variables, CCI scores and socio-demographic
and lifestyle variables. Model B included a priori variables, and variables independently
associated (statistically significant at P ≤ 0.05) with both outcome and exposure. Model C
included a priori variables and variables that were both significantly (P ≤ 0.05) associated
with 30-day mortality and changed the crude measure of effect by ≥10%. Results are
presented as odds ratios (OR), hazard ratios (HR) and 95% confidence intervals (CI).
Effect modification was assessed using the likelihood ratio test and Model C was re-run
stratified by significant interaction terms. Additionally, we performed a sensitivity analysis
where we adjusted for the number of GP visits (included as a covariate) in each of the three
models—A, B and C.
All analyses were carried out in Stata 13 (StataCorp. 2009. Stata Statistical Software:
Release 11. College Station, TX, USA: StataCorp LP).
RESULTS
The final analysis sample after excluding patients aged 30 years or younger was 201,179 who
had a MAARI episode from 2008 to 2013. Of the study population 200,083 (95%) survived
at the end of 30-day follow up, of which 40.8% were males and had a median age of 52. Of
the surviving group, 27,095 were statin users and 611 were currently using fibrates. Crude
analysis showed a significant increased association between statin exposure and 30-day
mortality [crude OR: 1.55 (95% CI [1.34–1.81])] (Table 1). All disease variables were
significantly associated with 30-day mortality as were all socio-demographic and lifestyle
variables.
All three multivariable logistic regression models yielded statistically significant point
estimates ranging from 0.63 to 0.67 as shown in Table 2. There was no effect modification
of the association between statins and 30-day mortality by either gender or BMI. However,
a significant interaction was found for CCI scores and therefore, in line with the analysis
strategy, Model C was re-run stratified by CCI score categories. The results of stratification
showed point estimates ranged from 0.48 to 0.63 but with overlapping 95% confidence
intervals (Table 3).
The proportional hazards assumption was fulfilled as determined using log–log plots
and the Schoenfeld global test. Crude analysis found an increase in the hazard for 30-day
mortality of 58% in the statin users group [crude HR: 1.58 (95% CI [1.36–1.83])].
Multivariable Cox proportional hazard regression analyses were conducted using the
previously outlined multivariable model building strategy and yielded significant point
estimates ranging from 0.66 to 0.70 (Table 4).
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Table 1 Comparison of patient characteristics among non-statin users and current statin users.
Patient characteristic Non-statin users
(n= 174,084)
Current statin users
(n= 27,095)
Unadjusted ORa(95%
confidence interval)
P valueb
Median age (IQR)c 49 (39–63) 69 (60–77) 1.06 (1.06–1.07) <0.001
Sex
Males 68,108 (39.1%) 13,962 (51.5%) 1
Females 105,976 (60.9 %) 13,133 (48.6%) 0.60 (0.59–0.62) <0.001
Hypertension 29,086 (16.2%) 13,377 (49.4%) 4.86 (4.73–4.99) <0.001
Myocardial infarction 3,134 (1.9%) 3,774 (13.9%) 8.34 (7.94–8.75) <0.001
Heart failure 1,410 (0.8%) 958 (3.5%) 4.49 (4.13–4.88) <0.001
Peripheral vascular disease 1,076 (0.6%) 991 (3.7%) 6.10 (5.59–6.66) <0.001
Chronic lung disease 31,689 (18.2%) 6,041 (22.3%) 1.29 (1.25–1.33) <0.001
Diabetes 10,162 (5.8%) 8,901 (32.9%) 7.89 (7.64–8.15) <0.001
Charlson’s comorbidity
score
0 135,609 (77.9%) 10,315 (38.1%) 1
1–2 29,257 (16.8%) 10,707 (39.5%) 4.81 (4.67–4.96)
3–5 7,021 (4.0%) 4,476 (16.5%) 8.39 (8.03–8.75)
>5 2,197 (1.3%) 1,597 (5.9%) 9.56 (8.93–10.22) <0.001
Fibrates 363 (0.2%) 248 (0.9%) 4.42 (3.76–5.20) <0.001
Glitazones 233 (0.1%) 690 (2.6%) 19.50 (16.80–22.63) <0.001
Metformin 2,009 (1.2%) 4,608 (17.0%) 17.55 (16.63–18.53) <0.001
Beta blockers 3,452 (2.0%) 4,310 (15.9%) 9.35 (8.92–9.80) <0.001
ARB 4,056 (2.3%) 4,089 (15.1%) 7.45 (7.12–7.80) <0.001
Smoking status
Never-smoker 21,812 (18.7%) 2,627 (14.7%) 1
Ex-smoker 66,505 (57.4%) 8,475 (47.4%) 1.06 (1.01–1.12)
Current-smoker 27,654 (23.9) 6,765 (37.9%) 2.03 (1.94–2.13) <0.001f
BMId
Underweight 2,433 (2.3%) 251 (1.5%) 1
Normal weight 38,461 (36.5%) 3,817 (22.2%) 0.97 (0.84–1.10)
Overweight 37,522 (35.6%) 6,815 (39.6%) 1.77 (1.55–2.02)
Obese 26,983 (25.6%) 6,295 (36.7%) 2.27 (1.99–2.59) <0.001f
Mean difference (95% CI) p-value
Mean number of GP
consultations(SD)e
213.06 (165.25) 376.82 (229.27) 163.76 (−166.01–161.52) <0.001
Notes.
aOdds ratio.
bWald’s p values.
cInterquartile range.
dBody mass index.
eStandard Deviation.
fWald’s p value for trend.
Significant p values shown in bold.
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Table 2 The association between statins and 30-day mortality followingMAARI.
ORa 95% CIb P-Value
Crude 1.55 1.34–1.81 <0.001
Model Ac 0.67 0.54–0.83 <0.001
Model Bd 0.63 0.51–0.78 <0.001
Model Ce 0.65 0.52–0.80 <0.001
Notes.
aOdds Ratio
bConfidence Interval
cAdjusted for a priori confounders, all comorbidity variables, all drug covariate variables, all potential confounding variables
dAdjusted for a priori confounders, variables significantly associated with both outcome and exposure (≤0.05)
eAdjusted for a priori confounders, variables significantly associated with both outcome and exposure and altering the crude OR
by ≥10%
Variables included in models A, B and C detailed in Appendix S2
Significant P- values shown in bold
Table 3 The association between statins and 30-day mortality followingMAARI: stratification by
Charlson’s Comorbidity Index categories.
Adjusted ORa 95% CIb P value
Comorbidity index score 0 0.63 0.45–0.89 0.008c
Comorbidity index score 1–2 0.57 0.43–0.79 0.001
Comorbidity index score 3–5 0.48 0.43–0.79 <0.001
Comorbidity index score >5 0.73 0.48–1.09 0.126
Notes.
aOdds Ratio
bConfidence Interval
cLRT p value
Significant p values shown in bold
Table 4 Hazard ratios (95% CI) representing the association between statin exposure and 30-day mor-
tality followingMAARI.
HRa 95% CIb P Value
Crude 1.58 1.36–1.83 <0.001
Model Ac 0.70 0.57–0.83 0.001
Model Bd 0.66 0.53–0.81 0.001
Model Ce 0.67 0.55–0.83 <0.001
Notes.
aHazard Ratio
bConfidence Interval
cAdjusted for a priori confounders, all comorbidity variables, all drug covariate variables, all potential confounding variables
dAdjusted for a priori confounders, variables significantly associated with both outcome and exposure (≤0.05)
eAdjustedfor a priori confounders, variables significantly associated with both outcome and exposure and altering the crude HR
by ≥10%
Variables included in models A, B and C detailed in Appendix S2
Significant p values shown in bold
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Sensitivity analysis
Statin users in our study sample were more likely (p< 0.001) to consult GPs than non-
users (Table 1). We performed a sensitivity analysis where we adjusted for number of
GP consultations in our multivariable models. After adjustment of number of GP visits,
we obtained very similar estimates to our primary results: Model A, OR (95% CI): 0.67
(0.54–0.84); Model B: 0.63 (0.51–0.78); Model C: 0.65 (0.52–0.80). All three estimates were
statistically significant (p< 0.001).
DISCUSSION
Summary of main findings
The findings of this study suggest that the use of statins is associated with decreased
mortality in the 30 days following a MAARI. Following adjustments for myocardial
infarction, hypertension, heart failure, diabetes, CCI and BMI (fully adjusted model C),
current statin use was protective and decreased the odds of MAARI-related mortality
by 30%. Cox regression analysis showed a similar decrease in 30-day mortality hazard
among statin users of 35%. We found a significant interaction for the effect of statins
with comorbidity as measured using the CCI and while stratification showed significant
protective effects of statins in the lower comorbidity categories, the 95% confidence
intervals were overlapping suggesting no clinically meaningful effect modifications. Fibrate
use was found to decrease MAARI-related mortality, but the results were non-significant.
Strengths and limitations
The validity of this study is enhanced by the quality, comprehensiveness and
representativeness of the data recorded within CPRD (Herrett et al., 2010). Additionally,
the large sample exceeds a priori sample size estimates (Appendix S3), therefore increasing
statistical power and reducing type II errors. Moreover, utilisation of contemporary data
makes the findings potentially applicable to current prescribing patterns. The retrospective
cohort design of this study eliminates temporal bias and there is no risk of recall bias as
data are prospectively added to CPRD and there is no risk of reverse causation as the
outcome of death is final. It is however, possible that miscoded entries due to user error
may cause systematic errors and could result in non-differential misclassification bias,
pushing findings towards the null hypothesis.
All General Practitioner (GP) issued prescriptions are recorded within the database thus
minimising misclassification bias. While prescriptions issued in secondary care facilities
are not accounted for in CPRD, long-term medication for chronic conditions like statins,
fibrates, glitazones and metformin are mostly prescribed in primary care. Moreover,
prescriptions are a proxy measure of drug use and assume patient compliance. Lack of
compliancewould lead tomisclassification of exposure status and lead to an over-estimation
of the association observed and push findings towards the null hypothesis. The present study
assumes patient compliance to prescriptions based on indirect evidence that most patients
do take prescribed drugs especially long-term medication (Jick et al., 2003). Moreover, this
study assumes that those without a prescription for statins are non-users, however it is
possible that individuals who have a clinical indication for receiving stations but refuse
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treatment have been omitted from the study sample and could therefore overestimate the
measure of effect. Furthermore, this study assumes that although there may be differences
in patients who were prescribed statins and those who were not, i.e., confounding by
indication leading to an overestimation of the observed effect, these differences would be
accounted for in the multivariable regression models.
Selection bias is minimised due to the method of data collection in CPRD, however
a possible limitation of CPRD data analysis is that MAARI patients presenting directly
to secondary institutions (and presumably, more severe cases) may not be included, and
therefore, these findings may only be applicable to those with less severe MAARI that can
be managed in primary care.
Finally, it is not possible to prove a causal relationship between statin use and MAARI
related mortality based on an observational study; to strengthen the causal inference we
adjusted for a variety of drug, disease, socio-demographic and lifestyle covariates. However,
an important limitation with observational studies is that of residual confounding and
omitted variable bias. It is possible that, despite our attempts to adjust for relevant
confounders, incorrect measurement of a particular independent variable or omission of
an unknown confounding variable could affect our estimates. We attempted to overcome
confounding by indication by estimating propensity scores. However, our propensity
scores could be limited by potentially omitted variables.
We earlier stated that there may be behavioural factors related to statin use that we
may not have been able to measure and subsequently adjust for in our analysis. There is
evidence to suggest that statin users are more likely to adopt a healthcare seeking lifestyle
resulting in them being healthier than non-users (Brookhart et al., 2007). This ‘healthy
user effect’ (i.e., statin users are healthier than non-users) has been proposed as one likely
explanation for previously observed statin-related benefits in infection. However in our
study sample, statin users were significantly more likely to have a history of hypertension,
myocardial infarction, heart failure, peripheral vascular disease, chronic lung disease and
higher number of comorbidities; statin users were also more likely to be current smokers
and obese (Appendix S4). These factors explain why the crude effect estimates showed
a higher likelihood of MAARI-related mortality in statin users. In line with previous
evidence (Brookhart et al., 2007), statin users in our study sample were more likely to visit
their physicians. However, when we adjusted for the number of GP visits, our estimates did
not change substantially. It is also important to note that the increased number of GP visits
among statin users may reflect genuine sicker patients with increased healthcare needs
rather than being indicative of a healthier lifestyle and it is unlikely that we have been able
to fully account for the healthy user effect. However, this study doesn’t account for people
whomay have had elevated cholesterol, but were contraindicated for statin therapy because
they were likely to experience side effects, not likely to take or adhere to prescriptions or
were too frail. Patient frailty, although difficult to measure in study, has not been accounted
for, contributing to residual confounding and should be taken into consideration when
interpreting the findings from this study. Finally, we have not performed instrumental
variable analysis, a method described in the literature (Polgreen et al., 2015) to account for
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non-random treatment assignment in observational studies investigating treatment effects,
in this current study; this is a limitation of this study.
Comparison with previous work
Statins and mortality
Existing research concurs with the protective association of statin use and MAARI-related
mortality results from this study (Frost et al., 2007;Myles et al., 2014). Similarly, data from
the Centre for Disease Control and Prevention (CDC) influenza hospitalisation surveillance
system (Vandermeer et al., 2012), showed a similar yet more conservative protective effect
was reported, [adj. OR 0.59 (95% CI [0.38–0.92])] and could be due to Vandermeer et
al. adjusting for age and comorbidity variables in-line with those included in the present
study as well as, influenza vaccination status and race; additional variables unaccounted
for in this study. Moreover, Vandermeer and colleagues considered patients requiring
hospitalisation for influenza hence were more seriously ill and therefore the capacity to
benefit is likely to have been greater. Similarly, Myles et al. reported a significant reduction
in pneumonia-related mortality among current statin users using data extracted from The
Health Improvement Network (THIN), a UK primary healthcare database similar to CPRD
and could not find evidence for the ‘healthy user effect.’ Finally a Canadian retrospective
cohort study (Kwong, Li & Redelmeier, 2009) linking multiple administrative health-care
databases over a 10 year period found borderline protective effects of statin exposure
in relation to 30-day mortality following influenza diagnosis [crude OR: 0.92 (95% CI
[0.89–0.95])] and a larger protective effect following pneumonia diagnosis [crude: OR
0.84 (95% CI [0.77–0.91])]; however, both estimates shifted towards the null following
adjustment. This could be due to misclassification of exposure status as statin use was not
captured during hospitalisation of patients.
One randomised controlled trial performed in intensive care units in France,
investigating the effect of simvastatin treatment on mortality in patients with ventilator-
associated pneumonia reported no significant difference in 28-day mortality between the
statin and the placebo groups [Hazard Ratio (HR): 1.45 (95% CI [0.83–2.51])] (Papazian
et al., 2013). Another trial performed in hospitalised patients with community-acquired
pneumonia showed no significant difference in time from hospital admission to clinical
stability between patients treated with simvastatin and placebo (median: 3 days (IQR: 2–5)
vs 3 days (IQR: 2–5); p-value: 0.47)) (Viasus et al., 2015). The 2012 JUPITER trial studied
the effect of rosuvastatin treatment on incident pneumonia in healthy patients reported a
modest benefit of statin treatment on the incidence of pneumonia (Novack et al., 2012).
While previous observational studies have reported a protective effect of statins, evidence
from randomised controlled trials show little of no effect of statins on pneumonia.
One explanation for this difference in estimates could be that the observational studies
described above were carried out mostly using primary care datasets, whereas the trials
have been carried out in intensive care units and hospitalised patients where patients were
demonstrably more ill. Polgreen et al., (2015) in their cohort study investigating the effect of
statins on pneumonia, have tried to minimise limitations of an observational study design
by performing instrumental variable analysis to account for non-random assignment of
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statin treatment. They reported that while statins were associated with a reduction in
pneumonia incidence in their initial analysis, this protective effect of statins was not seen
after accounting for non-random statin assignment indicating that the protective effect
seen initially was most likely due to healthy user effect (Polgreen et al., 2015).
The findings in this study suggest that statins may confer mortality-reduction benefits
in patients with MAARI. However, it should be noted that observational studies alone
cannot prove a conclusive causal relationship between statin exposure and decreased
30-day mortality following MAARI and associations observed may be attributable to
residual confounding; therefore, the findings of this study should be considered in the
context of other studies across different populations and animal studies when considering
the clinical implications. Nonetheless, the observed mortality reduction among statin
users are biologically plausible as their immunomodulatory action has been demonstrated
in animal and laboratory studies (Raggatt & Partridge, 2002; Liao & Laufs, 2005; Farmer,
2000; Davignon, 2004) and therefore, they could benefit MAARI patients by mediating
their immune response. However, prior to widespread use in this context, especially
among patients in whom statins would not otherwise be clinically indicated, randomised
control trials are required to confirm these potential benefits. It would also be valuable to
investigate whether the mortality reduction benefits vary for the different types of statins,
the duration of statin exposure and, explicit categorical definitions of statin dosage.
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